Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
3 "Hyungjin Rhee"
Filter
Filter
Article category
Publication year
Review Articles
Imaging differentiation of hepatocellular carcinoma, combined hepatocellular-cholangiocarcinoma, and intrahepatic cholangiocarcinoma: pitfalls and advances
Jaeseung Shin, Taek Chung, Sang Yun Ha, Hyungjin Rhee
Received February 22, 2026  Accepted March 4, 2026  Published online March 5, 2026  
DOI: https://doi.org/10.17998/jlc.2026.03.05    [Accepted]
  • 99 Views
  • 2 Downloads
AbstractAbstract PDF
Accurate non-invasive differentiation of primary liver cancers, such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and combined hepatocellular-cholangiocarcinoma (cHCC-CCA), is crucial for optimal management but challenging due to shared risk factors and overlapping imaging phenotypes. While the Liver Imaging Reporting and Data System LR-M category effectively captures the classic targetoid appearance of large duct type iCCA, the small duct type frequently exhibits HCC-mimicking non-rim arterial phase hyperenhancement and non-peripheral washout, potentially compromising diagnostic specificity. Furthermore, cHCC-CCA presents a formidable diagnostic dilemma, existing on a continuous imaging spectrum that reflects its histologic dominance. This continuous imaging spectrum not only blurs radiologic distinctions but also complicates tissue sampling, limiting the diagnostic accuracy of core needle biopsies and highlighting the risk of misclassification. To enhance diagnostic clarity, this review highlights their key imaging hallmarks: while HCC typically shows non-rim arterial phase hyperenhancement (APHE) and non-peripheral washout, large duct iCCA displays a classic targetoid appearance with rim APHE and progressive central enhancement. Conversely, small duct iCCA often mimics HCC, and cHCC-CCA exhibits a variable spectrum depending on its predominant histologic component. Ultimately, overcoming these diagnostic pitfalls requires a rigorous, multidisciplinary approach that synthesizes imaging findings, serologic tumor markers, and clinical contexts.
Close layer
Radiologic features of hepatocellular carcinoma related to prognosis
Shin Hye Hwang, Hyungjin Rhee
J Liver Cancer. 2023;23(1):143-156.   Published online March 9, 2023
DOI: https://doi.org/10.17998/jlc.2023.02.16
  • 10,718 Views
  • 268 Downloads
  • 17 Citations
AbstractAbstract PDF
The cross-sectional imaging findings play a crucial role in the diagnosis of hepatocellular carcinoma (HCC). Recent studies have shown that imaging findings of HCC are not only relevant for the diagnosis of HCC, but also for identifying genetic and pathologic characteristics and determining prognosis. Imaging findings such as rim arterial phase hyperenhancement, arterial phase peritumoral hyperenhancement, hepatobiliary phase peritumoral hypointensity, non-smooth tumor margin, low apparent diffusion coefficient, and the LR-M category of the Liver Imaging-Reporting and Data System have been reported to be associated with poor prognosis. In contrast, imaging findings such as enhancing capsule appearance, hepatobiliary phase hyperintensity, and fat in mass have been reported to be associated with a favorable prognosis. Most of these imaging findings were examined in retrospective, single-center studies that were not adequately validated. However, the imaging findings can be applied for deciding the treatment strategy for HCC, if their significance can be confirmed by a large multicenter study. In this literature, we would like to review imaging findings related to the prognosis of HCC as well as their associated clinicopathological characteristics.

Citations

Citations to this article as recorded by  
  • Association of Signal Heterogeneity in the Hepatobiliary Phase of Gd‐EOB‐DTPA‐Enhanced MRI With Survival Outcomes and Tumor Microenvironment in Hepatocellular Carcinoma
    Munetoshi Akaoka, Koichiro Haruki, Jun Woo, Kazuyoshi Ohki, Kenei Furukawa, Shinji Onda, Masashi Tsunematsu, Michinori Matsumoto, Yoshihiro Shirai, Toru Ikegami
    Journal of Hepato-Biliary-Pancreatic Sciences.2026;[Epub]     CrossRef
  • A Nomogram Based on MRI Visual Decision Tree to Evaluate Vascular Endothelial Growth Factor in Hepatocellular Carcinoma
    Hanting Dai, Chuan Yan, Wanrong Huang, Yifan Pan, Feng Pan, Yamei Liu, Shunli Wang, Huifang Wang, Rongping Ye, Yueming Li
    Journal of Magnetic Resonance Imaging.2025; 61(2): 970.     CrossRef
  • Prediction early recurrence of hepatocellular carcinoma after hepatectomy using gadoxetic acid-enhanced MRI and IVIM
    Da Guo, Liping Liu, Yu Jin
    European Journal of Radiology Open.2025; 14: 100643.     CrossRef
  • MRI Imaging Biomarkers for Prognostication of Hepatocellular Carcinoma
    Ja Kyung Yoon, Jin-Young Choi
    Journal of the Korean Society of Radiology.2025; 86(3): 364.     CrossRef
  • Radiologic and Pathologic Discordance in Hepatocellular Carcinoma: More Than a Mismatch, with Prognostic Significance
    Ijin Joo
    Gut and Liver.2025; 19(4): 477.     CrossRef
  • Contrast-enhanced MRI for identifying the steatohepatitic hepatocellular carcinoma from small hepatocellular carcinoma
    Jiachen Liu, Xiurong Ding, Yanyan Zhang, Hongjun Li
    Abdominal Radiology.2025;[Epub]     CrossRef
  • Proposal of a Mathematical Model for Motion Blur in MRI Images
    Tatsuya Kondo, Hiroaki Saito, Tsutomu Kanazawa
    Japanese Journal of Radiological Technology.2025; 81(11): n/a.     CrossRef
  • Prognostic prediction of primary liver cancer following transcatheter arterial chemoembolization (TACE) combined with targeted immunotherapy based on CT morphological characteristics
    Disi Liu
    American Journal of Cancer Research.2025; 15(11): 5014.     CrossRef
  • Radiomics and machine learning based on preoperative MRI for predicting extrahepatic metastasis in hepatocellular carcinoma patients treated with transarterial chemoembolization
    Gang Peng, Xiaojing Cao, Xiaoyu Huang, Xiang Zhou
    European Journal of Radiology Open.2024; 12: 100551.     CrossRef
  • Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma
    Ji Yeon Lee, Pil Soo Sung
    Gut and Liver.2024; 18(4): 558.     CrossRef
  • Advances in Understanding Hepatocellular Carcinoma Vasculature: Implications for Diagnosis, Prognostication, and Treatment
    Hyungjin Rhee, Young Nyun Park, Jin-Young Choi
    Korean Journal of Radiology.2024; 25(10): 887.     CrossRef
  • Inter-reader agreement for CT/MRI LI-RADS category M imaging features: a systematic review and meta-analysis
    Dong Hwan Kim, Sang Hyun Choi
    Journal of Liver Cancer.2024; 24(2): 192.     CrossRef
  • Gd-EOB-DTPA-enhanced MR imaging features of hepatocellular carcinoma in non-cirrhotic liver
    Mingyue Song, Yuhao Tao, Hanjun Zhang, Mingzhan Du, Lingchuan Guo, Chunhong Hu, Weiguo Zhang
    Magnetic Resonance Imaging.2024; 114: 110241.     CrossRef
  • Prediction of PD-L1 expression in unresectable hepatocellular carcinoma with gadoxetic acid-enhanced MRI
    Jun Gu Kang, Kyunghwa Han, Taek Chung, Hyungjin Rhee
    European Journal of Radiology.2024; 181: 111772.     CrossRef
  • The histopathological and molecular heterogeneity of hepatocellular carcinoma: a narrative review
    Wonju Chung, Haeryoung Kim
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Features Can Predict Immune-Excluded Phenotype of Hepatocellular Carcinoma
    Eisuke Ueshima, Keitaro Sofue, Takahiro Kodama, Shuhei Yamamoto, Masato Komatsu, Shohei Komatsu, Nobuaki Ishihara, Akihiro Umeno, Takeru Yamaguchi, Masatoshi Hori, Takumi Fukumoto, Tetsuo Takehara, Takamichi Murakami
    Liver Cancer.2024; 14(3): 271.     CrossRef
  • Imaging prognostication and tumor biology in hepatocellular carcinoma
    Diana Kadi, Marilyn F. Yamamoto, Emily C. Lerner, Hanyu Jiang, Kathryn J. Fowler, Mustafa R. Bashir
    Journal of Liver Cancer.2023; 23(2): 284.     CrossRef
Close layer
Update on Pathologic and Radiologic Diagnosis of Combined Hepatocellular-Cholangiocarcinoma
Hyungjin Rhee, Jae Hyon Park, Young Nyun Park
J Liver Cancer. 2021;21(1):12-24.   Published online March 31, 2021
DOI: https://doi.org/10.17998/jlc.21.1.12
  • 11,443 Views
  • 378 Downloads
  • 6 Citations
AbstractAbstract PDF
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a malignant primary liver carcinoma characterized by the unequivocal presence of both hepatocytic and cholangiocytic differentiation within the same tumor. Recent research has highlighted that cHCC-CCAs are more heterogeneous than previously expected. In the updated consensus terminology and WHO 2019 classification, “classical type” and “subtypes with stem-cell features” of the WHO 2010 classification are no longer recommended. Instead, it is recommended that the presence and percentages of various histopathologic components and stem-cell features be mentioned in the pathologic report. The new terminology and classification enable the exchange of clearer and more objective information about cHCC-CCAs, facilitating multi-center and multinational research. However, there are limitations to the diagnosis of cHCC-CCA by imaging and biopsy. cHCC-CCAs showing typical imaging findings of HCC could be misdiagnosed as HCC and subjected to inappropriate treatment, if other clinical findings are not sufficiently considered. cHCC-CCAs showing at least one of the CCA-like imaging features or unusual clinical features should be subjected to biopsy. There may be a sampling error for the biopsy diagnosis of cHCC-CCA. An optimized diagnostic algorithm integrating clinical, radiological, and histopathologic information of biopsy is required to resolve these diagnostic pitfalls.

Citations

Citations to this article as recorded by  
  • Combined Hepatocellular-Cholangiocarcinoma: A Clinical and Molecular Review
    Shaodian Xu, Julien Calderaro
    Seminars in Liver Disease.2025; 45(04): 476.     CrossRef
  • Enhancing liver cirrhosis varices and CSPH risk prediction with spleen stiffness measurement using 100-Hz probe
    Jeong-Ju Yoo, Sun Ah Maeng, Young Chang, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Gab Jin Cheon, Young Seok Kim, Hong Soo Kim, Sang Gyune Kim
    Scientific Reports.2024;[Epub]     CrossRef
  • MRI features of combined hepatocellular-cholangiocarcinoma
    Noor Fatima Majeed, Mathew Macey, Marta Braschi Amirfarzan, Sheida Sharifi, Jeremy R Wortman
    Abdominal Radiology.2024; 50(1): 169.     CrossRef
  • Imaging findings of intrahepatic cholangiocarcinoma for prognosis prediction and treatment decision-making: a narrative review
    Jun Gu Kang, Taek Chung, Dong Kyu Kim, Hyungjin Rhee
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Differentiation between hepatic angiomyolipoma and hepatocellular carcinoma in individuals who are not at-risk for hepatocellular carcinoma
    Sungtae Park, Myeong-Jin Kim, Kyunghwa Han, Jae Hyon Park, Dai Hoon Han, Young Nyun Park, Jaehyo Kim, Hyungjin Rhee
    European Journal of Radiology.2023; 166: 110957.     CrossRef
  • The Human TOR Signaling Regulator Is the Key Indicator of Liver Cancer Patients’ Overall Survival: TIPRL/LC3/CD133/CD44 as Potential Biomarkers for Early Liver Cancers
    Soo Young Jun, Hyang Ran Yoon, Ji-Yong Yoon, Su-Jin Jeon, Jeong-Ju Lee, Debasish Halder, Jin-Man Kim, Nam-Soon Kim
    Cancers.2021; 13(12): 2925.     CrossRef
Close layer

JLC : Journal of Liver Cancer
TOP